While Cg Oncology Inc has overperformed by 2.86%, investors are advised to look at stock chart patterns for technical insight.
On October 24, 2024, UBS started tracking Cg Oncology Inc (NASDAQ: CGON) recommending Buy. A report published by RBC Capital Mkts on September 23, 2024, Initiated its previous ‘Outperform’ rating for CGON. ROTH MKM also rated CGON shares as ‘Buy’, setting a target price of $65 on the company’s shares in an initiating report dated August 28, 2024. BofA Securities Initiated an Buy rating on June 28, 2024, and assigned a price target of $65. Morgan Stanley initiated its ‘Overweight’ rating for CGON, as published in its report on February 20, 2024. Goldman’s report from February 20, 2024 suggests a price prediction of $42 for CGON shares, giving the stock a ‘Neutral’ rating. Cantor Fitzgerald also rated the stock as ‘Overweight’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Cg Oncology Inc (CGON)
One of the most important indicators of Cg Oncology Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. Taking into account the quick ratio of the company, currently set at 35.32, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and CGON is recording 583.05K average volume. On a monthly basis, the volatility of the stock is set at 5.75%, whereas on a weekly basis, it is put at 4.70%, with a gain of 2.32% over the past seven days. Furthermore, long-term investors anticipate a median target price of $69.50, showing growth from the present price of $29.11, which can serve as yet another indication of whether CGON is worth investing in or should be passed over.
How Do You Analyze Cg Oncology Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 37.74%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 61.80% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CGON shares are owned by institutional investors to the tune of 61.80% at present.
